A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer
A phase 3 trial of Trastuzumab, Trastuzumab rezetecan, Adebrelimab, Capecitabine and Pembrolizumab in triple-negative breast cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
Overview
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer is a phase 3 interventional study registered as NCT07679360 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 1000 participants planned, started 2026-09-02 and due to reach its primary completion in 2030-12. Interventions recorded: Trastuzumab Rezetecan for Injection, Adebrelimab Injection, Capecitabine tablets and Pembrolizumab injection.
Similar pages
not linked directly; found by shared links- TrialA Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
Shares Trastuzumab rezetecan, Capecitabine, Trastuzumab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialPh1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
Shares Trastuzumab rezetecan, Adebrelimab, Capecitabine, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Shares Trastuzumab rezetecan, Trastuzumab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Trastuzumab rezetecan, Trastuzumab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.